Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM)

Brian G.M. Durie, MD, Shaji K. Kumar, MD, Saad Z. Usmani, MD, Bareng A.S. Nonyane, Eric A. Ammann, Annette Lam, Rachel Kobos, MD, Eric M Maiese, PhD, Thierry Facon, MD

Blood (2019) 134 (Supplement_1): 1830.

https://doi.org/10.1182/blood-2019-122937

Published: 2019

Journal Articles

Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and Indirect Treatment Comparison

Katja C. Weisel, MD, Sujith Dhanasiri, Aline Gauthier, Amie Padhiar, Eva Casal, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 2201.

https://doi.org/10.1182/blood-2019-123639

Published: 2019

Journal Articles

Estimating the Relative Treatment Effect and Corresponding Cost-Effectiveness Estimates of Inotuzumab Ozogamicin Vs. Blinatumomab for Adults with Philadelphia Chromosome-Negative (Ph-) Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in the United Kingdom (UK)

Simone Critchlow, Miranda Cooper, Ilse van Oostrum, Verna L Welch, PhD MPH, T. Alexander Russell-Smith

Blood (2019) 134 (Supplement_1): 3427.

https://doi.org/10.1182/blood-2019-123454

Published: 2019

Journal Articles

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Sophie Van Beekhuizen, MSc, Timothy J Bell, MHA, Ana Gezin, MSc, Joseph C Cappelleri, PhD MPH, MS, Bart Heeg, PhD, Carl Selya-Hammer, MSc, Majed Charaan, MSc, MBA, Geoffrey Chan, MD

Blood (2019) 134 (Supplement_1): 5846.

https://doi.org/10.1182/blood-2019-125852

Published: 2019

Journal Articles

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Gabriel Tremblay, DBA, MSc, BS, Geoffrey Chan, MD

Blood (2018) 132 (Supplement 1): 2709.

https://doi.org/10.1182/blood-2018-99-111931

Published: 2018

Journal Articles

A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide

Meletios A Dimopoulos, MD, Michele Cavo, MD, Maria-Victoria Mateos, MD PhD, Thierry Facon, Bart Heeg, PhD, Sophie van Beekhuizen, Sandhya Nair, Marta Pisini, MBA, Annette Lam, Mary Slavcev

Blood (2018) 132 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2018-99-113517

Published: 2018

Journal Articles

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

Irina Demmer, Susanne Huschens, Dietrich Potthoff, Jörg Tomeczkowski, Christian Englisch, Pushpike Thilakarathne, Joris Diels, Shaji K. Kumar, MD, Brian GM Durie, MD, Lewin Eisele

Blood (2018) 132 (Supplement 1): 3541.

https://doi.org/10.1182/blood-2018-99-116884

Published: 2018

Journal Articles

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Geoffrey Chan, MD, Gabriel Tremblay, DBA, MSc, BS

Blood (2018) 132 (Supplement 1): 1429.

https://doi.org/10.1182/blood-2018-99-111971

Published: 2018

Journal Articles

Incremental Survival with Nivolumab Relative to Standard of Care in Classical Hodgkin Lymphoma: A Canadian Analysis

Greta Lozano-Ortega, MSc, Basia Rogula, Karissa Johnston, Julie Villeneuve, Andriy Moshyk, Heather O'Brien, Clara Chen, PhD BS, MS, Joseph M. Connors, MD

Blood (2018) 132 (Supplement 1): 5894.

https://doi.org/10.1182/blood-2018-99-111278

Published: 2018

Journal Articles

Successful Field Test of a Combined Health Access Strategy and Novel Device to Screen for Sickle Cell Disease (SCD) in Rural Sub-Saharan Africa

Catherine Mupela Chunda-Liyoka, MD MSc, Ashok A Kumar, PhD BS, MS, Pauline M Sambo, MD, Felicity Lubinda, Tyler Humpton, Pauline Okuku, MSc, Chimuka Miyanda, Bsc, Justine Mulindwa, MD, Judy Im I, Kerry Maguire, MPH, George M Whitesides, Prof., Thomas P. Stossel, MD

Blood (2018) 132 (Supplement 1): 316.

https://doi.org/10.1182/blood-2018-99-114625

Published: 2018

Journal Articles

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Matthias Stelljes, MD, Yun Su, MD MPH, MS, Kyle Fahrbach, PhD, Erik Vandendries, MD PhD, Veronique Page, M.Sc, Uchenna Onyekwere, MD MPh, Yunyang Wang, M.Sc, M.Pharm, Joseph C. Cappelleri, PhD MPH, MS, Irina Proskorovsky, M.Sc

Blood (2017) 130 (Supplement 1): 2558.

https://doi.org/10.1182/blood.V130.Suppl_1.2558.2558

Published: 2017

Journal Articles

Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia

Gabriel Tremblay, DBA, MSc, BS, Menaka Bhor, PhD, Anuja Roy, PhD, Brian Elliott, MD, Mike Dolph, MSc BHSc, Anna Forsythe, PharmD, MSc, MBA, Andrew Briggs, DPhil

Blood (2017) 130 (Supplement 1): 2146.

https://doi.org/10.1182/blood.V130.Suppl_1.2146.2146

Published: 2017

Journal Articles

Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C Versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Gabriel Tremblay, DBA, MSc, BS, Bhakti Arondekar, BPharm, MBA, PhD, Geoffrey Chan, MD, Anastasiya Shor, PharmD, Anna Forsythe, PharmD, MSc, MBA, Su Yun, MD MPH

Blood (2017) 130 (Supplement 1): 5665.

https://doi.org/10.1182/blood.V130.Suppl_1.5665.5665

Published: 2017

Journal Articles

Benefit-Risk Comparison in Patients with Immune Thrombocytopenia (ITP) Receiving Eltrombopag or Romiplostim: Real World Evidence (RWE) from 26 Hospital Institutions

Anna Forsythe, PharmD, MSc, MBA, Anuja Roy, PhD, Menaka Bhor, PhD, Alex Allepuz, MD MPH, Maria Do Socorro Oliveira Portella, MD MBA, Christina Kwon, BSc, MSc, PhD, Gabriel Tremblay, DBA, MSc, BS

Blood (2017) 130 (Supplement 1): 3409.

https://doi.org/10.1182/blood.V130.Suppl_1.3409.3409

Published: 2017

Journal Articles

Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients

Bogdan Muresan, MS, Carla Mamolo, PhD, Joseph C. Cappelleri, PhD MPH, MS, Mark Shapiro, MD PhD, Rocco J. Crescenzo, DO, FACOI, Yun Su, MD MPH, Bart Heeg, PhD

Blood (2016) 128 (22): 3095.

https://doi.org/10.1182/blood.V128.22.3095.3095

Published: 2016

Journal Articles

Efficacy of Treatments in Relapsed or Relapsed and Refractory Multiple Myeloma: An Indirect Treatment Comparison

Paul G. Richardson, Jae Hoon Lee, MD PhD, Istvan Majer, Arun Krishna, Richard C. Woodman, MD

Blood (2014) 124 (21): 2638.

https://doi.org/10.1182/blood.V124.21.2638.2638

Published: 2014

Journal Articles

Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Carolina Reyes, PhD, Gregory Gazauskas, PhD, Ursula Becker, MSc, Santiago Moreno, David L. Veenstra, PharmD, PhD

Blood (2014) 124 (21): 1324.

https://doi.org/10.1182/blood.V124.21.1324.1324

Published: 2014

Journal Articles

No Outcome Differences Were Observed Between Supra-Diaphragmatic and Infra-Diaphragmatic Lesions in Limited-Stage Diffuse Large B Cell Lymphoma Treated with R-CHOP Therapy, Whereas the Presence of Gastro-Intestinal Lesions Was Associated with a Favorable Prognosis

Blood (2014) 124 (21): 1662.

https://doi.org/10.1182/blood.V124.21.1662.1662

Published: 2014

Journal Articles

Cost-Effectiveness Of Lenalidomide and Bortezomib In Patients With Previously Untreated Multiple Myeloma (MM)

Gerry Oster, PhD, Ariel Berger, MPH, Rebecca Bornheimer, BA, Gary Binder, MBA, Yasir Nagarwala, MD

Blood (2013) 122 (21): 5604.

https://doi.org/10.1182/blood.V122.21.5604.5604

Published: 2013

Journal Articles

Nanoparticle Design For Bone-Specific Chemotherapy and Microenvironmental Targeting In Multiple Myeloma

Michaela R Reagan, PhD, Archana Swami, PhD, Pamela A Basto, Yuji Mishima, PhD, Jinhe Liu, Siobhan Glavey, MD, Grace B O'Callaghan, PhD, Michele Moschetta, MD, Kenichi Nagano, DDS, Ph.D, Roland Baron, DDS, PhD, Aldo M Roccaro, MD, PhD, Omid Farokhzad, MD, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 881.

https://doi.org/10.1182/blood.V122.21.881.881

Published: 2013

NARROW

Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM)

Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and Indirect Treatment Comparison

Estimating the Relative Treatment Effect and Corresponding Cost-Effectiveness Estimates of Inotuzumab Ozogamicin Vs. Blinatumomab for Adults with Philadelphia Chromosome-Negative (Ph-) Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in the United Kingdom (UK)

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Incremental Survival with Nivolumab Relative to Standard of Care in Classical Hodgkin Lymphoma: A Canadian Analysis

Successful Field Test of a Combined Health Access Strategy and Novel Device to Screen for Sickle Cell Disease (SCD) in Rural Sub-Saharan Africa

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia

Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C Versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Benefit-Risk Comparison in Patients with Immune Thrombocytopenia (ITP) Receiving Eltrombopag or Romiplostim: Real World Evidence (RWE) from 26 Hospital Institutions

Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients

Efficacy of Treatments in Relapsed or Relapsed and Refractory Multiple Myeloma: An Indirect Treatment Comparison

Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

No Outcome Differences Were Observed Between Supra-Diaphragmatic and Infra-Diaphragmatic Lesions in Limited-Stage Diffuse Large B Cell Lymphoma Treated with R-CHOP Therapy, Whereas the Presence of Gastro-Intestinal Lesions Was Associated with a Favorable Prognosis

Cost-Effectiveness Of Lenalidomide and Bortezomib In Patients With Previously Untreated Multiple Myeloma (MM)

Nanoparticle Design For Bone-Specific Chemotherapy and Microenvironmental Targeting In Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only